A phase IV open-label evaluation of safety, tolerability and patient acceptance of raltegravir (MK-0518) combined with a fixed-dose formulation of tenofovir [emtricitabine/tenofovir disoproxil fumarate] following potential exposure to HIV-1

Trial Profile

A phase IV open-label evaluation of safety, tolerability and patient acceptance of raltegravir (MK-0518) combined with a fixed-dose formulation of tenofovir [emtricitabine/tenofovir disoproxil fumarate] following potential exposure to HIV-1

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jan 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top